Global Huntingtons Disease Therapeutics Market

Huntingtons Disease Therapeutics Comprehensive Study by Application (Health Care Centres, Hospitals), Distribution Channel (Online, Hospital Pharmacies), Medication Type (Antidopaminergics, Anticonvulsants, Antipsychotics, Antidepressants), Strength (6 MG, 9 MG, 12 MG) Players and Region - Global Market Outlook to 2030

Huntingtons Disease Therapeutics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 19.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Huntingtons Disease Therapeutics Market Overview:
This is an inherited disease in which the nerve cells degrade in the central nervous system. The disease has a wide impact on the functional abilities of the affected patient and it usually results in movement and thinking disabilities. Most people prone to this disease start showing signs and symptoms at their age of 30 -40. If the disease begins before the age of 20 it is known as Juvenile Huntington’s disease. Both men and women can be patients with the disease. Recently, only two symptom-alleviating therapies are specifically approved by FDA for Huntington’s disease are Xenazine and Austedo. The disease can also lead to swallowing and speech problems. Xenazine the drug which is approved by the US Food and Drug administration works by reducing the amount of dopamine in the brain of patients with Huntington’s disease. Dopamine is known as chemical messengers that transmit signals between nerve cells. It is said that chorea is caused by a surge in the activity of dopamine. Austedo the other approved drug works in the same way as Xenazine. The loss of motor control affects the life of a person negatively as it restricts the life of the person to carry out regular activities and can cause difficulty. A significant behavior change and cognition disorder associated with Huntington’s disease is depression that results due to brain injury and loss of brain function. As per latest study released by AMA Research, the Global Huntingtons Disease Therapeutics market is expected to see growth rate of 19.2%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Intense Research and Development in Bio-Medicine Specific to Genetic Disorders

Market Growth Drivers:
A Surge in Medical Insurance Covers for The Entire Family and Improvement in Medical Infrastructure

Challenges:
Lack of Medical Professionals

Restraints:
High Cost of Treatment and Less Awareness About the Treatment in The Under-Developed Countries

Opportunities:
Increased Investment by Many Pharmaceutical Companies in the Research and Development Sector to Develop Innovative and Curative Drugs

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Teva Pharmaceutical Industries (Israel), Alnylam Pharmaceuticals, Inc. (United States), AmpliPhi Biosciences Corp (United States), Pfizer (United States), Ipsen (France), Lundbeck (Denmark), Prana Biotechnology Ltd. (Australia), Valeant Pharmaceuticals International Inc. (Canada), Cortex Pharmaceuticals Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), GlaxoSmithKline (United Kingdom), Auspex Pharmaceuticals (United States), Ceregene Inc (United States) and SOM Biotech (Spain). Additionally, following companies can also be profiled that are part of our coverage like Raptor Pharmaceutical (United States) and Palobiofarma (Spain). Analyst at AMA Research see United States Players to retain maximum share of Global Huntingtons Disease Therapeutics market by 2030. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Huntingtons Disease Therapeutics market. Considering Market by Medication Type, the sub-segment i.e. Antidopaminergics will boost the Huntingtons Disease Therapeutics market. Considering Market by Strength, the sub-segment i.e. 6 MG will boost the Huntingtons Disease Therapeutics market.

Latest Market Insights:


In September 2021, NeuExcell Therapeutics Inc entered a partnership with Spark Therapeutics, Inc. (F. Hoffmann La Roche Ltd. owned subsidiary) for the development of gene therapy for treating HD patients. Under the terms of the agreement, NeuExcell Therapeutics is entitled to receive upfront license fees, R&D, and sales milestone payments of up to approximately USD 190 million and additional product royalties.

What Can be Explored with the Huntingtons Disease Therapeutics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Huntingtons Disease Therapeutics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Huntingtons Disease Therapeutics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Huntingtons Disease Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Huntingtons Disease Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Huntington's Disease Therapeutics, Venture Capitalists and Private Equity Firms and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Health Care Centres
  • Hospitals
By Distribution Channel
  • Online
  • Hospital Pharmacies

By Medication Type
  • Antidopaminergics
  • Anticonvulsants
  • Antipsychotics
  • Antidepressants

By Strength
  • 6 MG
  • 9 MG
  • 12 MG

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Surge in Medical Insurance Covers for The Entire Family
      • 3.2.2. Improvement in Medical Infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Lack of Medical Professionals
    • 3.4. Market Trends
      • 3.4.1. Intense Research and Development in Bio-Medicine Specific to Genetic Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Huntingtons Disease Therapeutics, by Application, Distribution Channel, Medication Type, Strength and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Huntingtons Disease Therapeutics (Value)
      • 5.2.1. Global Huntingtons Disease Therapeutics by: Application (Value)
        • 5.2.1.1. Health Care Centres
        • 5.2.1.2. Hospitals
      • 5.2.2. Global Huntingtons Disease Therapeutics by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Hospital Pharmacies
      • 5.2.3. Global Huntingtons Disease Therapeutics by: Medication Type (Value)
        • 5.2.3.1. Antidopaminergics
        • 5.2.3.2. Anticonvulsants
        • 5.2.3.3. Antipsychotics
        • 5.2.3.4. Antidepressants
      • 5.2.4. Global Huntingtons Disease Therapeutics by: Strength (Value)
        • 5.2.4.1. 6 MG
        • 5.2.4.2. 9 MG
        • 5.2.4.3. 12 MG
      • 5.2.5. Global Huntingtons Disease Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Huntingtons Disease Therapeutics (Price)
  • 6. Huntingtons Disease Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alnylam Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AmpliPhi Biosciences Corp (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ipsen (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lundbeck (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Prana Biotechnology Ltd. (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Valeant Pharmaceuticals International Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cortex Pharmaceuticals Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Vertex Pharmaceuticals Incorporated (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GlaxoSmithKline (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Auspex Pharmaceuticals (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Ceregene Inc (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. SOM Biotech (Spain)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Huntingtons Disease Therapeutics Sale, by Application, Distribution Channel, Medication Type, Strength and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Huntingtons Disease Therapeutics (Value)
      • 7.2.1. Global Huntingtons Disease Therapeutics by: Application (Value)
        • 7.2.1.1. Health Care Centres
        • 7.2.1.2. Hospitals
      • 7.2.2. Global Huntingtons Disease Therapeutics by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Hospital Pharmacies
      • 7.2.3. Global Huntingtons Disease Therapeutics by: Medication Type (Value)
        • 7.2.3.1. Antidopaminergics
        • 7.2.3.2. Anticonvulsants
        • 7.2.3.3. Antipsychotics
        • 7.2.3.4. Antidepressants
      • 7.2.4. Global Huntingtons Disease Therapeutics by: Strength (Value)
        • 7.2.4.1. 6 MG
        • 7.2.4.2. 9 MG
        • 7.2.4.3. 12 MG
      • 7.2.5. Global Huntingtons Disease Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Huntingtons Disease Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Huntingtons Disease Therapeutics: by Application(USD Million)
  • Table 2. Huntingtons Disease Therapeutics Health Care Centres , by Region USD Million (2018-2023)
  • Table 3. Huntingtons Disease Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 4. Huntingtons Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 5. Huntingtons Disease Therapeutics Online , by Region USD Million (2018-2023)
  • Table 6. Huntingtons Disease Therapeutics Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 7. Huntingtons Disease Therapeutics: by Medication Type(USD Million)
  • Table 8. Huntingtons Disease Therapeutics Antidopaminergics , by Region USD Million (2018-2023)
  • Table 9. Huntingtons Disease Therapeutics Anticonvulsants , by Region USD Million (2018-2023)
  • Table 10. Huntingtons Disease Therapeutics Antipsychotics , by Region USD Million (2018-2023)
  • Table 11. Huntingtons Disease Therapeutics Antidepressants , by Region USD Million (2018-2023)
  • Table 12. Huntingtons Disease Therapeutics: by Strength(USD Million)
  • Table 13. Huntingtons Disease Therapeutics 6 MG , by Region USD Million (2018-2023)
  • Table 14. Huntingtons Disease Therapeutics 9 MG , by Region USD Million (2018-2023)
  • Table 15. Huntingtons Disease Therapeutics 12 MG , by Region USD Million (2018-2023)
  • Table 16. South America Huntingtons Disease Therapeutics, by Country USD Million (2018-2023)
  • Table 17. South America Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 18. South America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 19. South America Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 20. South America Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 21. Brazil Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 22. Brazil Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 23. Brazil Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 24. Brazil Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 25. Argentina Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 26. Argentina Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 27. Argentina Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 28. Argentina Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 29. Rest of South America Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 31. Rest of South America Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 32. Rest of South America Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 33. Asia Pacific Huntingtons Disease Therapeutics, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 36. Asia Pacific Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 37. Asia Pacific Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 38. China Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 39. China Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 40. China Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 41. China Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 42. Japan Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 43. Japan Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 44. Japan Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 45. Japan Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 46. India Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 47. India Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 48. India Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 49. India Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 50. South Korea Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 51. South Korea Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 52. South Korea Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 53. South Korea Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 54. Taiwan Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 55. Taiwan Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 56. Taiwan Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 57. Taiwan Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 58. Australia Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 59. Australia Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 60. Australia Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 61. Australia Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 66. Europe Huntingtons Disease Therapeutics, by Country USD Million (2018-2023)
  • Table 67. Europe Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 68. Europe Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 69. Europe Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 70. Europe Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 71. Germany Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 72. Germany Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 73. Germany Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 74. Germany Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 75. France Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 76. France Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 77. France Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 78. France Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 79. Italy Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 80. Italy Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 81. Italy Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 82. Italy Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 83. United Kingdom Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 85. United Kingdom Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 86. United Kingdom Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 87. Netherlands Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 88. Netherlands Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 89. Netherlands Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 90. Netherlands Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 91. Rest of Europe Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 93. Rest of Europe Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 94. Rest of Europe Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 95. MEA Huntingtons Disease Therapeutics, by Country USD Million (2018-2023)
  • Table 96. MEA Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 97. MEA Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 98. MEA Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 99. MEA Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 100. Middle East Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 101. Middle East Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 102. Middle East Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 103. Middle East Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 104. Africa Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 105. Africa Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 106. Africa Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 107. Africa Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 108. North America Huntingtons Disease Therapeutics, by Country USD Million (2018-2023)
  • Table 109. North America Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 110. North America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 111. North America Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 112. North America Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 113. United States Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 114. United States Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 115. United States Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 116. United States Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 117. Canada Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 118. Canada Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 119. Canada Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 120. Canada Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 121. Mexico Huntingtons Disease Therapeutics, by Application USD Million (2018-2023)
  • Table 122. Mexico Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 123. Mexico Huntingtons Disease Therapeutics, by Medication Type USD Million (2018-2023)
  • Table 124. Mexico Huntingtons Disease Therapeutics, by Strength USD Million (2018-2023)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Huntingtons Disease Therapeutics: by Application(USD Million)
  • Table 140. Huntingtons Disease Therapeutics Health Care Centres , by Region USD Million (2025-2030)
  • Table 141. Huntingtons Disease Therapeutics Hospitals , by Region USD Million (2025-2030)
  • Table 142. Huntingtons Disease Therapeutics: by Distribution Channel(USD Million)
  • Table 143. Huntingtons Disease Therapeutics Online , by Region USD Million (2025-2030)
  • Table 144. Huntingtons Disease Therapeutics Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 145. Huntingtons Disease Therapeutics: by Medication Type(USD Million)
  • Table 146. Huntingtons Disease Therapeutics Antidopaminergics , by Region USD Million (2025-2030)
  • Table 147. Huntingtons Disease Therapeutics Anticonvulsants , by Region USD Million (2025-2030)
  • Table 148. Huntingtons Disease Therapeutics Antipsychotics , by Region USD Million (2025-2030)
  • Table 149. Huntingtons Disease Therapeutics Antidepressants , by Region USD Million (2025-2030)
  • Table 150. Huntingtons Disease Therapeutics: by Strength(USD Million)
  • Table 151. Huntingtons Disease Therapeutics 6 MG , by Region USD Million (2025-2030)
  • Table 152. Huntingtons Disease Therapeutics 9 MG , by Region USD Million (2025-2030)
  • Table 153. Huntingtons Disease Therapeutics 12 MG , by Region USD Million (2025-2030)
  • Table 154. South America Huntingtons Disease Therapeutics, by Country USD Million (2025-2030)
  • Table 155. South America Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 156. South America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 157. South America Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 158. South America Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 159. Brazil Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 160. Brazil Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 161. Brazil Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 162. Brazil Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 163. Argentina Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 164. Argentina Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 165. Argentina Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 166. Argentina Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 167. Rest of South America Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 168. Rest of South America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 169. Rest of South America Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 170. Rest of South America Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 171. Asia Pacific Huntingtons Disease Therapeutics, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 173. Asia Pacific Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 174. Asia Pacific Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 175. Asia Pacific Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 176. China Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 177. China Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 178. China Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 179. China Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 180. Japan Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 181. Japan Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 182. Japan Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 183. Japan Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 184. India Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 185. India Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 186. India Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 187. India Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 188. South Korea Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 189. South Korea Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 190. South Korea Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 191. South Korea Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 192. Taiwan Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 193. Taiwan Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 194. Taiwan Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 195. Taiwan Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 196. Australia Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 197. Australia Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 198. Australia Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 199. Australia Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 204. Europe Huntingtons Disease Therapeutics, by Country USD Million (2025-2030)
  • Table 205. Europe Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 206. Europe Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 207. Europe Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 208. Europe Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 209. Germany Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 210. Germany Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 211. Germany Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 212. Germany Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 213. France Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 214. France Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 215. France Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 216. France Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 217. Italy Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 218. Italy Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 219. Italy Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 220. Italy Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 221. United Kingdom Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 222. United Kingdom Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 223. United Kingdom Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 224. United Kingdom Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 225. Netherlands Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 226. Netherlands Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 227. Netherlands Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 228. Netherlands Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 229. Rest of Europe Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 230. Rest of Europe Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 231. Rest of Europe Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 232. Rest of Europe Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 233. MEA Huntingtons Disease Therapeutics, by Country USD Million (2025-2030)
  • Table 234. MEA Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 235. MEA Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 236. MEA Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 237. MEA Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 238. Middle East Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 239. Middle East Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 240. Middle East Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 241. Middle East Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 242. Africa Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 243. Africa Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 244. Africa Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 245. Africa Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 246. North America Huntingtons Disease Therapeutics, by Country USD Million (2025-2030)
  • Table 247. North America Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 248. North America Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 249. North America Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 250. North America Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 251. United States Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 252. United States Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 253. United States Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 254. United States Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 255. Canada Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 256. Canada Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 257. Canada Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 258. Canada Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 259. Mexico Huntingtons Disease Therapeutics, by Application USD Million (2025-2030)
  • Table 260. Mexico Huntingtons Disease Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 261. Mexico Huntingtons Disease Therapeutics, by Medication Type USD Million (2025-2030)
  • Table 262. Mexico Huntingtons Disease Therapeutics, by Strength USD Million (2025-2030)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Huntingtons Disease Therapeutics: by Application USD Million (2018-2023)
  • Figure 5. Global Huntingtons Disease Therapeutics: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Huntingtons Disease Therapeutics: by Medication Type USD Million (2018-2023)
  • Figure 7. Global Huntingtons Disease Therapeutics: by Strength USD Million (2018-2023)
  • Figure 8. South America Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 10. Europe Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 11. MEA Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 12. North America Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 13. Global Huntingtons Disease Therapeutics share by Players 2023 (%)
  • Figure 14. Global Huntingtons Disease Therapeutics share by Players (Top 3) 2023(%)
  • Figure 15. Global Huntingtons Disease Therapeutics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2023
  • Figure 19. Alnylam Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Alnylam Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. AmpliPhi Biosciences Corp (United States) Revenue, Net Income and Gross profit
  • Figure 22. AmpliPhi Biosciences Corp (United States) Revenue: by Geography 2023
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2023
  • Figure 25. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 26. Ipsen (France) Revenue: by Geography 2023
  • Figure 27. Lundbeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. Lundbeck (Denmark) Revenue: by Geography 2023
  • Figure 29. Prana Biotechnology Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Prana Biotechnology Ltd. (Australia) Revenue: by Geography 2023
  • Figure 31. Valeant Pharmaceuticals International Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Valeant Pharmaceuticals International Inc. (Canada) Revenue: by Geography 2023
  • Figure 33. Cortex Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cortex Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Vertex Pharmaceuticals Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 36. Vertex Pharmaceuticals Incorporated (United States) Revenue: by Geography 2023
  • Figure 37. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Auspex Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 40. Auspex Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 41. Ceregene Inc (United States) Revenue, Net Income and Gross profit
  • Figure 42. Ceregene Inc (United States) Revenue: by Geography 2023
  • Figure 43. SOM Biotech (Spain) Revenue, Net Income and Gross profit
  • Figure 44. SOM Biotech (Spain) Revenue: by Geography 2023
  • Figure 45. Global Huntingtons Disease Therapeutics: by Application USD Million (2025-2030)
  • Figure 46. Global Huntingtons Disease Therapeutics: by Distribution Channel USD Million (2025-2030)
  • Figure 47. Global Huntingtons Disease Therapeutics: by Medication Type USD Million (2025-2030)
  • Figure 48. Global Huntingtons Disease Therapeutics: by Strength USD Million (2025-2030)
  • Figure 49. South America Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 50. Asia Pacific Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 51. Europe Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 52. MEA Huntingtons Disease Therapeutics Share (%), by Country
  • Figure 53. North America Huntingtons Disease Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries (Israel)
  • Alnylam Pharmaceuticals, Inc. (United States)
  • AmpliPhi Biosciences Corp (United States)
  • Pfizer (United States)
  • Ipsen (France)
  • Lundbeck (Denmark)
  • Prana Biotechnology Ltd. (Australia)
  • Valeant Pharmaceuticals International Inc. (Canada)
  • Cortex Pharmaceuticals Inc. (United States)
  • Vertex Pharmaceuticals Incorporated (United States)
  • GlaxoSmithKline (United Kingdom)
  • Auspex Pharmaceuticals (United States)
  • Ceregene Inc (United States)
  • SOM Biotech (Spain)
Additional players considered in the study are as follows:
Raptor Pharmaceutical (United States) , Palobiofarma (Spain)
Select User Access Type

Key Highlights of Report


Mar 2024 200 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Huntingtons Disease Therapeutics Market Quantitative research analysis
Global Huntingtons Disease Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Huntingtons Disease Therapeutics market are Teva Pharmaceutical Industries (Israel), Alnylam Pharmaceuticals, Inc. (United States), AmpliPhi Biosciences Corp (United States), Pfizer (United States), Ipsen (France), Lundbeck (Denmark), Prana Biotechnology Ltd. (Australia), Valeant Pharmaceuticals International Inc. (Canada), Cortex Pharmaceuticals Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), GlaxoSmithKline (United Kingdom), Auspex Pharmaceuticals (United States), Ceregene Inc (United States) and SOM Biotech (Spain), to name a few.
"Intense Research and Development in Bio-Medicine Specific to Genetic Disorders" is seen as one of major influencing trends for Huntingtons Disease Therapeutics Market during projected period 2023-2030.

Know More About Global Huntingtons Disease Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Ebola Virus Vaccine Comprehensive Study by Type (Live-attenuated Vaccines, Inactivated Vaccines, Others), Application (Hospitals and Clinics, Charity Organization), Diagnostic Tests (ELISA, Antigen-c...
$ 3750
Chickenpox Vaccine Comprehensive Study by Type (Monovalent Vaccine, Combination Vaccine), Application (Hospitals, Clinics, Laboratories), End User (Children, Adults) Players and Region - Global Marke...
$ 3500
Addiction Treatment Comprehensive Study by Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, Other Substance Addiction Treatment), Drug Type (Buprop...
$ 3750
Atopic Dermatitis Treatment Comprehensive Study by Route of Administration (Oral, Topical, Injectable), Treatment (Medications, Wet Dressings, Light Therapy, Others), Distribution Channel (Hospital P...
$ 3750
Axial Spondyloarthritis Treatment Comprehensive Study by Type (COX-2 Antagonists, COX Inhibitors, Others), Application (Hospital, Rehabilitation Center, Other), Distribution Channel (Online, Medical ...
$ 3650
Carotid Endarterectomy Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centre, Others), Diagnosis (Computed Tomography Angiography, Carotid Ultrasound, Magnetic Resonance ...
$ 3500